ArticleFrontiers in immunology2026
Multi-layer transcriptomic analyses identify a mucin-associated epithelial program linked to innate inflammatory injury in ulcerative colitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial barrier disruption and mucosal innate immune activation reinforce each other in ulcerative colitis (UC), yet the epithelial glycosylation programs linking mucus homeostasis to inflammatory tissue injury remain incompletely defined. Here, we integrated bulk, single-cell, and spatial transcriptomic analyses with functional validation to identify mucin-associated epithelial determinants relevant to UC. In the discovery cohort GSE107499, 15 dysregulated mucin-type O-glycosylation and mucin-associated genes were identified and were enriched mainly in O-glycan biosynthesis, glycosyltransferase activity, and Golgi-associated secretory functions. An integrative prioritization framework highlighted GALNT12 as the leading candidate. Low GALNT12 expression was associated with enrichment of TNFA signaling via NF-kB, inflammatory response, interferon gamma response, IL6-JAK-STAT3 signaling, and complement, together with higher infiltration scores for monocyte lineage cells, neutrophils, fibroblasts, and T-cell populations. At single-cell resolution, GALNT12 was concentrated in epithelial cells, particularly MUC2-positive epithelial cells. MUC2-positive epithelial cells with detectable GALNT12 expression showed broader inferred incoming and outgoing communication with surrounding epithelial, stromal, and immune populations and were enriched for proteostasis and secretory trafficking programs. Spatial transcriptomic analysis further identified GALNT12-high mucin-associated niches that co-localized with stronger goblet and mucin signatures and lower inflammatory scores. In HT29-19A cells, GALNT12 knockdown exacerbated TNF-α-induced LDH release, reduced OCLN and TJP1 expression, increased IL-8, IL-6, CCL2, IL-1β, and IL-18 production, and enhanced caspase-1 processing detected as cleaved caspase-1 p10 together with increased GSDMD-N formation under TNF-α stress. Collectively, these findings identify a GALNT12-centered mucin-associated epithelial program linked to epithelial barrier resilience and relatively restrained innate inflammatory injury at the barrier-immune interface in UC, while supporting a caspase-1/GSDMD-associated inflammatory injury phenotype under cytokine stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.